Aspen wants to buy Canadian pharmaceutical company Vivus for US$640 million
-
Last Update: 2014-06-04
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Source: e-medicine Facebook from June to April 29, 2014, Aspen Investment announced that it plans to purchase vivus, a Canadian pharmaceutical company, for us $640 million Vivus was founded in 1996, mainly engaged in the development of drugs in the fields of obesity, sleep disorders and sexual health Among them, the weight-loss drug qsymia (i.e compound phentermine and topiramate) was approved by FDA in 2012 However, the small company has a long way to go: in 2013, the company broke out agency wars, the trend of executives leaving, and the challenge from atvis generic The Aspen investment that launched the acquisition is relatively mysterious The company is said to have been registered in Nevada for only a few weeks, with its registered address on the U.S Coast Instead of buying shares, the company bought a number of options between May 16 and 23.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
